 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE reported it has further advanced its transdermal gel Zygelreceiving orphan drug designation from the European Commission EC for the gels active ingredient to treat 22q11.2 deletion syndrome 22q. Zygel, which contains cannabidiol, was previously granted orphan drug designation by the EC for the treatment of Fragile X syndrome FXS. 